Literature DB >> 21844905

Bladder cancer: validating the EORTC risk tables in BCG-treated patients.

David D Buethe, Wade J Sexton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21844905     DOI： 10.1038/nrurol.2011.118

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  9 in total

Review 1.  Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.

Authors:  M Craig Hall; Sam S Chang; Guido Dalbagni; Raj Som Pruthi; John Derek Seigne; Eila Curlee Skinner; J Stuart Wolf; Paul F Schellhammer
Journal:  J Urol       Date:  2007-12       Impact factor: 7.450

Review 2.  How to build and interpret a nomogram for cancer prognosis.

Authors:  Alexia Iasonos; Deborah Schrag; Ganesh V Raj; Katherine S Panageas
Journal:  J Clin Oncol       Date:  2008-03-10       Impact factor: 44.544

3.  Updated concepts and treatment of carcinoma in situ.

Authors:  D Lamm; H Herr; G Jakse; M Kuroda; F K Mostofi; E Okajima; A Sakamoto; I Sesterhenn; F C da Silva
Journal:  Urol Oncol       Date:  1998 Jul-Oct       Impact factor: 3.498

4.  Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.

Authors:  D L Lamm; B A Blumenstein; J D Crissman; J E Montie; J E Gottesman; B A Lowe; M F Sarosdy; R D Bohl; H B Grossman; T M Beck; J T Leimert; E D Crawford
Journal:  J Urol       Date:  2000-04       Impact factor: 7.450

5.  The role of tumor-free status in repeat resection before intravesical bacillus Calmette-Guerin for high grade Ta, T1 and CIS bladder cancer.

Authors:  Andrea Guevara; Laurent Salomon; Yves Allory; Guillaume Ploussard; Alexandre de la Taille; Alexandre Paul; René Yiou; Andras Hoznek; Mickaël Dahan; Claude-Clément Abbou; Dimitri Vordos
Journal:  J Urol       Date:  2010-06       Impact factor: 7.450

6.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

7.  The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables.

Authors:  Jesus Fernandez-Gomez; Rosario Madero; Eduardo Solsona; Miguel Unda; Luis Martinez-Piñeiro; Antonio Ojea; Jose Portillo; Manuel Montesinos; Marcelino Gonzalez; Carlos Pertusa; Jesus Rodriguez-Molina; Jose Emilio Camacho; Mariano Rabadan; Ander Astobieta; Santiago Isorna; Pedro Muntañola; Anabel Gimeno; Miguel Blas; Jose Antonio Martinez-Piñeiro
Journal:  Eur Urol       Date:  2011-05-25       Impact factor: 20.096

8.  Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder.

Authors:  Shahrokh F Shariat; Craig Zippe; Gerson Lüdecke; Hans Boman; Marta Sanchez-Carbayo; Roberto Casella; Christine Mian; Martin G Friedrich; Sanaa Eissa; Hideyuki Akaza; Ihor Sawczuk; Vincenzo Serretta; Hartwig Huland; Hans Hedelin; Raina Rupesh; Naoto Miyanaga; Arthur I Sagalowsky; Frank Wians; Claus G Roehrborn; Yair Lotan; Paul Perrotte; Serge Benayoun; Michael J Marberger; Pierre I Karakiewicz
Journal:  J Urol       Date:  2005-05       Impact factor: 7.450

9.  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

Authors:  Richard J Sylvester; Adrian P M van der Meijden; Willem Oosterlinck; J Alfred Witjes; Christian Bouffioux; Louis Denis; Donald W W Newling; Karlheinz Kurth
Journal:  Eur Urol       Date:  2006-01-17       Impact factor: 20.096
  9 in total
  2 in total

1.  Bladder cancer: validity of the 2004 system for grading Ta bladder cancer.

Authors:  Maximilian Burger; Peter J Goebell
Journal:  Nat Rev Urol       Date:  2012-02-14       Impact factor: 14.432

2.  Risk prediction scores for recurrence and progression of non-muscle invasive bladder cancer: an international validation in primary tumours.

Authors:  Moniek M Vedder; Mirari Márquez; Esther W de Bekker-Grob; Malu L Calle; Lars Dyrskjøt; Manoils Kogevinas; Ulrika Segersten; Per-Uno Malmström; Ferran Algaba; Willemien Beukers; Torben F Ørntoft; Ellen Zwarthoff; Francisco X Real; Nuria Malats; Ewout W Steyerberg
Journal:  PLoS One       Date:  2014-06-06       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.